Search Results - "Lincy, Jeremie"

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial by Bissler, John J, Prof, Kingswood, J Christopher, FRCP, Radzikowska, Elżbieta, MD, Zonnenberg, Bernard A, MD, Frost, Michael, MD, Belousova, Elena, Prof, Sauter, Matthias, MD, Nonomura, Norio, Prof, Brakemeier, Susanne, MD, de Vries, Petrus J, Prof, Whittemore, Vicky H, PhD, Chen, David, PhD, Sahmoud, Tarek, MD, Shah, Gaurav, MD, Lincy, Jeremie, MS, Lebwohl, David, MD, Budde, Klemens, Prof

“…Summary Background Angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mTOR), and are common in…”
Get full text

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary by Singh, Simron, Carnaghi, Carlo, Buzzoni, Roberto, Pommier, Rodney F, Raderer, Markus, Tomasek, Jiri, Lahner, Harald, Valle, Juan W, Voi, Maurizio, Bubuteishvili-Pacaud, Lida, Lincy, Jeremie, Wolin, Edward, Okita, Natsuko, Libutti, Steven K, Oh, Do-Youn, Kulke, Matthew, Strosberg, Jonathan, Yao, James C, Pavel, Marianne E, Fazio, Nicola

“…The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo…”
Get more information

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST‐MARKETING SURVEILLANCE ANALYSIS by Abboud, Miguel, Kanter, Julie, Marfo, Kwaku, Anthony, Charmaine, Lincy, Jeremie, Nassin, Michele, Joshi, Vikas, Brueckner, Andreas, Keefe, Deborah, Ataga, Kenneth I.

Get full text

Everolimus for Advanced Pancreatic Neuroendocrine Tumors by Yao, James C, Shah, Manisha H, Ito, Tetsuhide, Bohas, Catherine Lombard, Wolin, Edward M, Van Cutsem, Eric, Hobday, Timothy J, Okusaka, Takuji, Capdevila, Jaume, de Vries, Elisabeth G.E, Tomassetti, Paola, Pavel, Marianne E, Hoosen, Sakina, Haas, Tomas, Lincy, Jeremie, Lebwohl, David, Öberg, Kjell

“…A randomized study involving 410 patients with advanced pancreatic neuroendocrine tumors showed that everolimus, as compared with placebo, more than doubled…”
Get full text

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study by Ataga, Kenneth I., Kutlar, Abdullah, DeBonnett, Laurie, Lincy, Jeremie, Kanter, Julie

“…Background: Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS), chronic hemolysis, recurrent pain episodes called…”
Get full text

Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials by Kutlar, Abdullah, Joshi, Vikas, Brueckner, Andreas, Kanter, Julie, Liles, Darla K., Lincy, Jeremie, Manjare, Rahul, Adomakoh, Yvonne Dei, Heeney, Matthew M., de Montalembert, Mariane, Keefe, Deborah, Marfo, Kwaku, Ataga, Kenneth I.

“…Introduction: Crizanlizumab is a humanized monoclonal antibody that binds to P-selectin and blocks its interaction with its ligands, including P-selectin…”
Get full text

Reply to V. Amoroso et al by Yao, James C, Voi, Maurizio, Lincy, Jeremie, Pavel, Marianne

Get full text

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies by Kanter, Julie, Liles, Darla K, Smith-Whitley, Kim, Brown, Clark, Kutlar, Abdullah, Elliott, Brian, Shah, Amit, Lincy, Jeremie, Poggio, Susan, Ataga, Kenneth I.

“…Background: Crizanlizumab, a humanized monoclonal antibody that binds P-selectin and blocks interaction with its ligands (including leukocyte PSGL-1), is under…”
Get full text

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy by Hurvitz, Sara A., Dalenc, Florence, Campone, Mario, O’Regan, Ruth M., Tjan-Heijnen, Vivianne C., Gligorov, Joseph, Llombart, Antonio, Jhangiani, Haresh, Mirshahidi, Hamid R., Tan-Chiu, Elizabeth, Miao, Sara, El-Hashimy, Mona, Lincy, Jeremie, Taran, Tetiana, Soria, Jean-Charles, Sahmoud, Tarek, André, Fabrice

“…Increased activation of the PI3K/Akt/mTOR pathway is a common factor in putative mechanisms of trastuzumab resistance, resulting in dysregulation of cell…”
Get full text

Updated Results from the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): 145 by Wolin, Edward, Pommier, Rodney, Lincy, Jeremie, Winkler, Robert, Yao, James

Get full text

Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study by Yao, James C., Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward M., Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Bubuteishvili-Pacaud, Lida, Lincy, Jeremie, Valle, Juan W., Delle Fave, Gianfranco, Van Cutsem, Eric, Oh, Do-Youn, Strosberg, Jonathan R., Kulke, Matthew H., Pavel, Marianne E.

“…Abstract only…”
Get full text

Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial by Singh, Simron, Carnaghi, Carlo, Buzzoni, Roberto, Pommier, Rodney F., Raderer, Markus, Tomasek, Jiri, Lahner, Harald, Valle, Juan W., Voi, Maurizio, Bubuteishvili-Pacaud, Lida, Lincy, Jeremie, Sachs, Carolin, Okita, Natsuko, Libutti, Steven K., Oh, Do-Youn, Kulke, Matthew H., Strosberg, Jonathan R., Yao, James C., Pavel, Marianne E., Fazio, Nicola

“…Abstract only 315 Background: In the groundbreaking, phase 3 RCT RADIANT-4 study, everolimus (EVE) significantly prolonged median progression-free survival…”
Get full text

Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM) by Bissler, John, Kingswood, Christopher, Zonnenberg, B. A., Frost, Michael, Belousova, Elena, Radzikowska, Elzbieta, Sauter, Matthias, Nonomura, Norio, Brakemeier, Susan, de Vries, Petrus, Klimovsky, Judith, Shah, Gaurav D., Miao, Sara, Lincy, Jeremie, Budde, Klemens

“…Abstract only 4632 Background: EXIST-2 (NCT00790400) is a randomized, double-blind, placebo-controlled, phase 3 trial assessing the efficacy and safety of…”
Get full text